Co-Chairman of the Board · GoodRx Holdings, Inc. (GDRX)

Trevor Bezdek

A named executive officer of GoodRx in every fiscal year CompBrief holds from FY2019 to FY2025. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2025

$971,608

Salary $416,667Stock awards $466,593Bonus $169

FY2024: $853,918

4th of 6 named executive officers at GoodRx by FY2025 total.

6 named officers on file for GoodRx, FY2025

Trevor Bezdek’s pay file — $29

  • 7 fiscal years of pay, line by line
  • 2 equity grants, each cited to its filing
  • GDRX’s disclosed peer group of 22 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how GoodRx’s whole pay program stands against its peers

  • GoodRx’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on GDRX→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 29, 2026 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Trevor Bezdek’s full pay file as a PDF — free

More than this page: up to 10 years of Trevor’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Trevor Bezdek compensation by year

GoodRx Summary Compensation Table · all 7 fiscal years held
In US dollars, as GoodRx reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2019FY2020FY2021FY2022FY2023FY2024FY2025
Salary$500,000$500,000$500,000$500,000$500,000$500,000$416,667
Bonus$0$451$334$571$250$398$169
Stock awards$0$266,662,480$0$0$0$0$466,593
Option awards$0$0$0$0$0$0$0
Non-equity incentive$608,831$480,000$357,176$0$269,120$302,300$0
Pension and deferred compensation$0$0$0$0$0$0$0
All other$39,850$9,511$34,171$36,434$42,158$51,220$88,179
Total$1,148,681$267,652,442$891,681$537,005$811,528$853,918$971,608

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: GoodRx Holdings, Inc. DEF 14A filed April 29, 2026, accession 0001809519-26-000091, and prior-year filings. Open the filing on EDGAR.

How this page was built: the GoodRx Holdings, Inc. filed document, accession 0001809519-26-000091. Every figure is read from that document and cited to the page and table it appears in. Filed April 29, 2026.

$1.1M
$267.7M
$892K
$537K
$812K
$854K
$972K
FY19
FY20
FY21
FY22
FY23
FY24
FY25
SalaryBonusNon-equity incentiveStock awardsAll other

Equity holdings

unvested awards at FY2025 year-end
TypeUnvested unitsValue at year-endExercise price
RSU104,925$284,347—
RSU33,530$90,866—

Per the Outstanding Equity Awards at Fiscal Year-End table in GoodRx Holdings, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

4 Form 4 lines since the FY2025 proxy (filed April 29, 2026)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2026-11-02Exercise or conversion—34,975—378,785
2026-11-02Exercise or conversion derivative—34,975$0.0069,950
2026-06-16Grant or award—73,434$0.00343,810
2026-06-08Grant or award—110,294$0.00270,376

The 4 most recent of 4 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

Change-in-control & termination

estimated payments GoodRx discloses, by trigger · FY2024
TriggerCash severanceAccelerated equityBenefits continuationTotal as disclosed
Change in control and involuntary termination——$0$0
Disability——$0$0
Death——$0$0
Resignation for good reason, no change in control——$0$0
Involuntary termination without cause$0$0$0$0
Change in control, no termination——$0$0
Change in control and resignation for good reason——$0$0

Per the Potential Payments Upon Termination or Change in Control table in GoodRx Holdings, Inc.'s FY2024 proxy. Estimates as the company printed them; a dash means it printed no figure.

GoodRx’s named executive officers, FY2025

as the company reported each
Named executive officerRoleFY2025 total
Wendy BarnesChief Executive Officer & President$23,367,483
Christopher McGinnisChief Financial Officer & Treasurer$8,698,916
Romin NabieyChief Accounting Officer and Former Interim Chief Financial Officer$1,256,668
Trevor Bezdek · this pageCo-Chairman of the Board$971,608
Scott WagnerFormer Interim Chief Executive Officer$856,780
Karsten VoermannFormer Chief Financial Officer$280,256

Board service

GoodRx board · FY2021–FY2024

How this board is paid

Company policy: GoodRx pays directors a $30,000 cash retainer and $230,000 in RSUs. As stated in GoodRx's FY2024 proxy.

Committees

Innovation

The full GoodRx compensation record

free company brief

This page is one person within GoodRx's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the GoodRx proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are GoodRx's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Trevor Bezdek's compensation dossier · One-time report. No refunds.